Pharmacologic intervention to reduce chronic inflammation in people with HIV Page 1
Presented at AIDS 2022 – The 24th International AIDS Conference BACKGROUND • Chronic …

The treatment of metabolic disease is becoming an increasingly important component of the
long-term management of patients with well controlled HIV on antiretroviral therapy (ART) …

Psoriasis is an autoimmune condition in which the immune system attacks healthy skin cells,
causing the accelerated formation of new skin characterized by scaly patches or plaques …

Endocrine and metabolic dysfunction has been documented throughout the history of
clinical experience with HIV and AIDS. Opportunistic infections such as CMV and TB …

By significantly delaying the onset of AIDS, highly active antiretroviral therapy (HAART)
decreases the high rates of mortality and morbidity previously associated with HIV type 1 …

Αbstract The therapeutic management of human immunodeficiency virus infection/acquired
immunodeficiency syndrome (HIV/AIDS) is constantly evolving and improving. Newer drugs …

From the earliest recognized AIDS deaths in 1981 to the commencement of combination
antiretroviral therapy (ART) in the mid-1990s and the simpler combination ART regimens …

Morphologic and metabolic abnormalities, including subcutaneous adipose tissue wasting,
central adipose tissue accumulation, dyslipidemia and disorders of glucose metabolism are …

Human immunodeficiency virus (HIV) is a potentially life-threatening single-stranded RNA
lentivirus that attacks the body's immune system by infecting CD4 T lymphocytes. If …

PREVIEW Psoriasis, a T-cell-mediated disorder, affects 1% to 3% of the world's population.
The characteristic lesions occur in many different forms, can cause significant discomfort and …